We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Abrocitinib for Atopic Dermatitis Beats Dupixent in Phase 3 Study
Pfizer’s Abrocitinib for Atopic Dermatitis Beats Dupixent in Phase 3 Study
Pfizer said Monday that its atopic dermatitis treatment abrocitinib had demonstrated efficacy in a late-stage clinical trial that compared the treatment with Sanofi and Regeneron’s Dupixent (dupilumab).